HeartSciences Inc. (HSCS) Latest Filing Signal

Latest Filing: 10-Q  |  Filed Mar 16, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for HeartSciences Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-Q, HeartSciences Inc.'s filing signal continuing negative.
earningsVibe SuperAnalyst™ Verdict: CONTINUING NEGATIVE

Signal Performance — Stock Price Since Filing

30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Negative
GEMINI
Continuing Negative
CLAUDE
Turned Positive
CHATGPT
Continuing Negative

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does HeartSciences Inc. actually do?
Answer:
HeartSciences Inc. is a medical technology company focused on enhancing the clinical utility of electrocardiograms (ECGs) through artificial intelligence (AI). The company is developing AI-ECG algorithms to detect a broader range of cardiac conditions, aiming to make ECGs more valuable screening tools. Its product pipeline includes the MyoVista wav ECG device, a 12-lead resting ECG incorporating a proprietary AI-ECG algorithm for cardiac dysfunction detection, and the MyoVista Insights Cloud Platform, designed to host AI-ECG algorithms from internal and third-party developers on an ECG hardware-agnostic basis. HeartSciences' initial revenue model for the MyoVista wav ECG is expected to be 'razor-razorblade' with proprietary consumables, with future models incorporating algorithm usage and subscriptions. The company is headquartered in Southlake, Texas, and is currently seeking FDA clearance for its products.
Question:
What are HeartSciences Inc.'s revenue drivers?
Answer:
The company's primary revenue drivers are expected to be the sale of its MyoVista wav ECG device, associated proprietary consumables (electrodes), and recurring revenue from algorithm usage and subscriptions via the MyoVista Insights Cloud Platform.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required